GEIS-新闻详情

India declares 'Delta plus' a Covid-19 variant of concern

2021-06-23 00:00:00.0 海峡时报-亚洲原网页

BENGALURU (REUTERS) - India on Tuesday (June 22) declared a new coronavirus variant to be of concern, and said nearly two dozen cases had been detected in three states.

The variant, identified locally as "Delta plus", was found in 16 cases in the state of Maharashtra, Federal Health Secretary Rajesh Bhushan told a news conference.

The ministry said Delta plus showed increased transmissibility and advised states to increase testing.

On Monday, India vaccinated a record 8.6 million people as it began offering free shots to all adults, but experts doubted it could maintain that pace.

"This is clearly not sustainable," Dr Chandrakant Lahariya, an expert in public policy and health systems, told Reuters.

"With such one-day drives, many states have consumed most of their current vaccine stocks, which will affect the vaccination in days to follow."

With the currently projected vaccine supply for the next few months, the maximum daily achievable rate is four to five million doses, Dr Lahariya added.

The effort has so far covered about 5.5 per cent of the 950 million people eligible, even though India is the world's largest vaccine producer.

A devastating second wave during April and May overwhelmed health services, killing hundreds of thousands. Images of funeral pyres blazing in carparks raised questions over the chaotic vaccine roll-out.

Since May, vaccinations have averaged fewer than three million doses a day, far less than the 10 million health officials say are crucial to protect the millions vulnerable to new surges.

Particularly in the countryside, where two-thirds of a population of 1.4 billion lives and the healthcare system is often overstretched, the drive has faltered, experts say.

Maintaining the pace will prove challenging when it comes to injecting younger people in such areas, Delhi-based epidemiologist Rajib Dasgupta said.

The capital is also facing difficulties. The authorities in New Delhi said more than eight million residents had yet to receive a first dose and inoculating all adults there would take more than a year at the current pace.

India has been administering AstraZeneca's vaccine, made locally by the Serum Institute of India, and a home-grown shot named Covaxin, made by Bharat Biotech.